Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

PZ0020

Sigma-Aldrich

Temsirolimus

≥98% (HPLC)

Sinônimo(s):

42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin, CCI-779

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C56H87NO16
Número CAS:
Peso molecular:
1030.29
Número MDL:
Código UNSPSC:
12352200
ID de substância PubChem:
NACRES:
NA.77
Preço e disponibilidade não estão disponíveis no momento.

Nível de qualidade

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to off-white

solubilidade

DMSO: ≥20 mg/mL

temperatura de armazenamento

room temp

cadeia de caracteres SMILES

CO[C@@H]1CC(CC[C@H]1OC(=O)C(C)(CO)CO)C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](CC3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCCC4C(=O)O2)OC

InChI

1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

chave InChI

CBPNZQVSJQDFBE-FUXHJELOSA-N

Informações sobre genes

human ... FKBP1A(2280)

Descrição geral

Temsirolimus is an esterified rapamycin compound, soluble in water.[1]

Aplicação

Temsirolimus has been used:
  • in combination with radiation to study its effect on von Hippel Lindau (VHL) tumour suppressor gene-deficient renal carcinoma cell lines[2]
  • to induce autophagy[3]
  • as a mammalian target of rapamycin complex 1 (mTORC1) inhibitor to study the effect of cellular Akt-kinase on human papillomaviruses 16 (HPV16) late gene expression[4]

Ações bioquímicas/fisiológicas

Temsirolimus is a specific inhibitor of mammalian target of rapamycin (mTOR) mTOR Complex 1 (mTORC1). Temsirolimus is an antiproliferative and antiangiogenic, the first-in-class mTOR inhibitor approved for the treatment of patients with advanced poor prognosis renal cell carcinoma.
Temsirolimus is an antiproliferative and antiangiogenic mTORC1 inhibitor.
The inhibitory action of temsirolimus is mediated by FKBP-12 (FK506-binding protein 12), a major intracellular protein. It is useful in treating renal-cell carcinoma.[5]

Características e benefícios

This compound is featured on the PKB/Akt page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 6

1 of 6

Rapamycin Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus

Sigma-Aldrich

R8781

Rapamycin

Everolimus analytical standard

Supelco

94687

Everolimus

PP242 hydrate ≥98% (HPLC), powder

Sigma-Aldrich

P0037

PP242 hydrate

Sirolimus solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

S-015

Sirolimus solution

Temsirolimus
Ma WW and Jimeno A
Drugs Today (Barc), 43(10), 659-669 (2007)
Viktor Grünwald et al.
European urology, 70(6), 1006-1015 (2016-05-31)
The predictive role of objective remission remains undefined for targeted agents in metastatic renal cell carcinoma (mRCC); however, early tumour shrinkage (eTS) was shown to be predictive and/or prognostic for overall survival (OS) and progression-free survival (PFS) in mRCC in
Cynthia Guilbert et al.
PloS one, 8(12), e85995-e85995 (2014-01-07)
Inhibitors of the mammalian target of rapamycin (mTORi) have clinical activity; however, the benefits of mTOR inhibition by rapamycin and rapamycin-derivatives (rapalogs) may be limited by a feedback mechanism that results in AKT activation. Increased AKT activity resulting from mTOR
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Hudes G, et al.
The New England Journal of Medicine, 356(22), 2271-2281 (2007)
C Le Tourneau et al.
British journal of cancer, 99(8), 1197-1203 (2008-09-18)
The proof of principle that a drug targeting mTOR can improve survival has been obtained recently from a large randomised trial using temsirolimus as a first-line therapy in patients with advanced poor prognostic renal cell carcinoma. Consistent data have recently

Artigos

We offer many products related to PKB/Akt for your research needs.

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica